Beijing Wantai Biological Pharmacy Enterprise Past Earnings Performance
Past criteria checks 0/6
Beijing Wantai Biological Pharmacy Enterprise has been growing earnings at an average annual rate of 28%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 29.1% per year.
Key information
28.0%
Earnings growth rate
27.0%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 29.1% |
| Return on equity | -1.6% |
| Net Margin | -7.2% |
| Next Earnings Update | 25 Oct 2024 |
Recent past performance updates
Recent updates
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year
Jul 26
These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well
Jul 22Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings
Apr 04Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade
Apr 02Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%
Feb 28Revenue & Expenses Breakdown
How Beijing Wantai Biological Pharmacy Enterprise makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2,713 | -194 | 995 | 1,188 |
| 31 Mar 24 | 3,377 | 128 | 1,214 | 1,165 |
| 31 Dec 23 | 5,511 | 1,248 | 1,936 | 1,177 |
| 30 Sep 23 | 7,504 | 2,600 | 2,541 | 1,524 |
| 30 Jun 23 | 9,419 | 3,745 | 3,197 | 1,318 |
| 31 Mar 23 | 10,901 | 4,650 | 3,509 | 1,203 |
| 31 Dec 22 | 11,185 | 4,736 | 3,581 | 1,091 |
| 30 Sep 22 | 10,805 | 4,777 | 3,455 | 604 |
| 30 Jun 22 | 9,716 | 3,993 | 3,123 | 708 |
| 31 Mar 22 | 8,098 | 3,063 | 2,779 | 705 |
| 31 Dec 21 | 5,750 | 2,021 | 1,958 | 677 |
| 30 Sep 21 | 4,351 | 1,398 | 1,554 | 570 |
| 30 Jun 21 | 3,475 | 1,155 | 1,232 | 382 |
| 31 Mar 21 | 2,867 | 896 | 1,011 | 343 |
| 31 Dec 20 | 2,354 | 677 | 834 | 309 |
| 30 Sep 20 | 1,953 | 551 | 704 | 243 |
| 30 Jun 20 | 1,504 | 368 | 552 | 223 |
| 31 Mar 20 | 1,244 | 239 | 516 | 178 |
| 31 Dec 19 | 1,184 | 209 | 511 | 164 |
| 30 Sep 19 | 1,096 | 217 | 472 | 149 |
| 30 Jun 19 | 1,054 | 269 | 455 | 141 |
| 31 Mar 19 | 1,007 | 279 | 428 | 134 |
| 31 Dec 18 | 983 | 293 | 421 | 137 |
| 31 Dec 17 | 950 | 150 | 362 | 158 |
| 31 Dec 16 | 844 | 148 | 350 | 128 |
| 31 Dec 15 | 681 | 119 | 269 | 109 |
| 31 Dec 14 | 596 | 118 | 322 | 0 |
| 31 Dec 13 | 499 | 80 | 272 | 0 |
Quality Earnings: 603392 is currently unprofitable.
Growing Profit Margin: 603392 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603392 is unprofitable, but has reduced losses over the past 5 years at a rate of 28% per year.
Accelerating Growth: Unable to compare 603392's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603392 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.1%).
Return on Equity
High ROE: 603392 has a negative Return on Equity (-1.56%), as it is currently unprofitable.